HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”

This article was originally published in The Rose Sheet

Executive Summary

Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency
Advertisement

Related Content

FDA Will Consider Triclosan For OTC Acne Monograph Inclusion
Non-Alcohol Antiseptic Hand Products Should Prove Efficacy – NDAC
Non-Alcohol Antiseptic Hand Products Should Prove Efficacy – NDAC
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Triclosan Efficacy Studies Support “Significant” Antimicrobial Effect – Ciba
Triclosan Antiseptic Category I Status Requested By CIBA
Advertisement
UsernamePublicRestriction

Register

RS013793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel